The Food and Drug Administration Feb. 28 announced it is making important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins.
Among other things, the changes remove the need for routine periodic monitoring of liver enzymes in patients taking statins. The drugs’ labels also will include information about memory loss and confusion in some patients taking the drugs.
The statin products include Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe).
“We want health ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.